Safety and tolerability of andecaliximab as monotherapy and in combination with an anti-PD-1 antibody in Japanese patients with gastric or gastroesophageal junction adenocarcinoma: a phase 1b study

Yoshikawa, AK; Yamaguchi, K; Muro, K; Takashima, A; Ichimura, T; Sakai, D; Kadowaki, S; Chin, K; Kudo, T; Mitani, S; Kitano, S; Thai, D; Zavodovskaya, M; Liu, J; Boku, N; Satoh, T

Satoh, T (通讯作者),Osaka Univ, Grad Sch Med, Dept Frontier Sci Canc & Chemotherapy, Osaka, Japan.

JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022; 10 (1):